Navigation Links
VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
Date:7/28/2008

SAN JOSE, Calif., July 28 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, today announced its plans to present at the BMO Capital Markets 2008 Focus on Healthcare Conference, to be held August 5-6, 2008, at the Millennium Broadway Hotel in New York City.

VNUS' presentation is currently scheduled for 10:00 a.m. ET on Wednesday, August 6, and will be webcast on the corporate website at http://ir.vnus.com/events.cfm. The management speakers will be Brian Farley, President and Chief Executive Officer, and Peter Osborne, Chief Financial Officer and Vice President of Finance and Administration. An archive of the webcast will be available through August 6, 2009.

About VNUS Medical Technologies, Inc.

VNUS is a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that is often the underlying cause of painful varicose veins. VNUS sells the Closure(R) system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. Approximately 300,000 patients have been treated to date with VNUS Closure catheters. For more information, please visit the corporate website at http://www.vnus.com .


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
2. Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008
3. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
4. Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. Saving Certified Continuing Medical Education (CME)
7. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
8. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
9. RADI Medical Systems Launches Next Generation PressureWire(R) Certus
10. BioElectronics ActiPatch(TM) Product Chosen as One of 9 Medical Breakthroughs That May Change Your Life
11. Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... ChanTest, the leading expert in ion channels and ... development, and safety -- is one of eight organizations ... and Commercialization Program. Governor Ted Strickland and Interim Director ... the Ohio Third Frontier Commission, Mark Barbash, announced the ...
... Aegera Therapeutics is pleased to announce the initiation ... AEG33773, a novel, orally bio-available small molecule therapeutic ... , The Phase 2a study, entitled A Multicenter, ... Efficacy of AEG33773 versus Placebo in Patients with ...
... May 6 iZumi Bio, Inc., a biotechnology ... stem cell (iPS) technology with the mission of ... differentiation of patient cells, today announced the appointments ... (CTO) and Dushyant Pathak, Ph.D., as vice president ...
Cached Biology Technology:ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 3
(Date:4/17/2014)... State University engineer has developed a patented technique ... explosive devices. The same technique could help police ... M. and Kay L. Theede chair in engineering ... and his research team have created a template-based ... car trunks. The distance detection method called ...
(Date:4/17/2014)... White House honored Clemson professor Rajendra Singh Thursday ... to promote and expand solar deployment in the ... D. Houser Banks Professor of Electrical and Computer ... Nanoelectronics, is considered a local hero leading the ... economic opportunity in solar power and driving policy ...
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... (SALT LAKE CITY)Alternating hemiplegia of childhood (AHC) is a ... episodes of paralysis and stiffness, first affecting one side ... and disappear, again and again, and affected children often ... older, children fall progressively behind their peers in both ...
... smog-filled sky or a contaminated river, according to a ... for the prosperous. People living in China,s cities ... more likely to begreen: re-using their plastic grocery bags ... the international journal AMBIO , indicates that the ...
... doesn,t mean making a trip to the local pharmacy for ... the forest to provide a pharmacopeia of medicines to ... But while questions persist about whether such natural remedies are ... examining the phenomenon from a unique perspective, and trying to ...
Cached Biology News:Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 2Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 3Pollution can make citizens - both rich and poor - go green 2Health care savings, naturally 2Health care savings, naturally 3
NORMAL DONOR DONKEY SERUM...
Human SIGIRR MAb (Clone 162201)...
Mouse TrkC Affinity Purified Polyclonal Ab...
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Biology Products: